Ocular Therapeutix (OCUL) Times Interest Earned (2013 - 2026)
Ocular Therapeutix (OCUL) posted quarterly Times Interest Earned of -$29.41 for Q2 2026, down 31.13% year-over-year from -$42.7 in Q2 2025, and up 12.5% on a QoQ basis from -$33.61 in Q1 2026.
Powered by 
Analysis
Ocular Therapeutix (OCUL) Times Interest Earned (2013 - 2026) Analysis & Trends
Ocular Therapeutix has reported Times Interest Earned for 14 years, with the latest figure at -$29.41 in Q2 2026.
- Times Interest Earned for Q2 2026 came in at -$29.41, down 31.13% year-over-year; the trailing twelve-month figure through Jun 2026 was -$27.53 (down 48.78% YoY), and the FY2025 annual result was -$0.92, down 21.07% from the prior year.
- Times Interest Earned advanced to -$29.41 in Q2 2026, from -$33.61 in the prior quarter.
- Over five years, Times Interest Earned peaked at $33.38 in Q4 2022 and troughed at -$33.61 in Q1 2026.
- A 5-year average of -$12.17 and a median of -$13.2 in 2024 frame the typical range for Times Interest Earned.
- The widest annual swing landed in 2022, when Times Interest Earned jumped 190.44%; it then sank 778.49% in 2025.
- A 5-year view of Times Interest Earned shows it stood at $33.38 in 2022, then tumbled by 65.14% to $11.64 in 2023, then slumped by 239.93% to -$16.28 in 2024, then plunged by 51.28% to -$24.63 in 2025, then declined by 19.39% to -$29.41 in 2026.
- Per Business Quant data, the three most recent Times Interest Earned figures were -$29.41 in Q2 2026, -$33.61 in Q1 2026, and -$24.63 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | -493.00 |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | -21.24 |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | 8.18 |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 2.82 |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - | 1.42 |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | -0.08 |
| 10 | Ocular Therapeutix | 2.41 Bn | 2.41 Bn | 11.46 Mn | -29.41 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -29.41 |
| Mar 31, 2026 | -33.61 |
| Dec 31, 2025 | -24.63 |
| Sep 30, 2025 | -22.88 |
| Jun 30, 2025 | -22.43 |
| Mar 31, 2025 | -21.42 |
| Dec 31, 2024 | -16.28 |
| Sep 30, 2024 | -14.27 |
| Jun 30, 2024 | -13.64 |
| Mar 31, 2024 | -7.80 |
| Dec 31, 2023 | -4.83 |
| Sep 30, 2023 | -5.61 |
| Jun 30, 2023 | -10.33 |
| Mar 31, 2023 | -12.75 |
| Dec 31, 2022 | -10.48 |
| Sep 30, 2022 | -11.99 |
| Jun 30, 2022 | -11.74 |
| Mar 31, 2022 | -10.60 |
| Dec 31, 2021 | -10.74 |
| Sep 30, 2021 | -11.78 |